CY1933A - Novel compounds - Google Patents

Novel compounds

Info

Publication number
CY1933A
CY1933A CY193390A CY193390A CY1933A CY 1933 A CY1933 A CY 1933A CY 193390 A CY193390 A CY 193390A CY 193390 A CY193390 A CY 193390A CY 1933 A CY1933 A CY 1933A
Authority
CY
Cyprus
Prior art keywords
novel compounds
anchor
less
gpiii
gpii
Prior art date
Application number
CY193390A
Other languages
English (en)
Inventor
Alex Bollen
Diane Gregoire
Michel Heinderckx
Paul Jacobs
Marc Massaer
Original Assignee
Smithkline Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Biolog filed Critical Smithkline Biolog
Publication of CY1933A publication Critical patent/CY1933A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrically Driven Valve-Operating Means (AREA)
  • Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
  • Liquid Crystal (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY193390A 1989-06-27 1990-06-22 Novel compounds CY1933A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37177289A 1989-06-27 1989-06-27

Publications (1)

Publication Number Publication Date
CY1933A true CY1933A (en) 1990-06-22

Family

ID=23465352

Family Applications (1)

Application Number Title Priority Date Filing Date
CY193390A CY1933A (en) 1989-06-27 1990-06-22 Novel compounds

Country Status (14)

Country Link
EP (1) EP0405867B1 (fr)
JP (1) JPH0349694A (fr)
KR (1) KR0166585B1 (fr)
AT (1) ATE119939T1 (fr)
AU (1) AU625328B2 (fr)
CA (1) CA2019845A1 (fr)
CY (1) CY1933A (fr)
DE (1) DE69017769T2 (fr)
DK (1) DK0405867T3 (fr)
ES (1) ES2071770T3 (fr)
IE (1) IE66516B1 (fr)
NZ (1) NZ234222A (fr)
PT (1) PT94479B (fr)
ZA (1) ZA904915B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
ES2150906T3 (es) * 1990-10-04 2000-12-16 Res Corp Technologies Inc Antigeno del virus varicella-zoster.
WO1994002596A1 (fr) * 1992-07-17 1994-02-03 Merck & Co., Inc. Methode de prevention d'herpes-zoster ou de soulagement de nevralgie post-herpetique associee a la varicelle
GB9226768D0 (en) * 1992-12-23 1993-02-17 Smithkline Beecham Biolog Vaccines
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
KR970006484A (ko) * 1995-07-27 1997-02-21 수두 바이러스의 당단백질을 대량발현시키는 동물세포주
KR100365986B1 (ko) * 1996-02-09 2003-02-20 스미스클라인 비이참 바이오로지칼즈 에스.에이. 수두대상포진바이러스유전자63생성물에대한백신
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
KR100434023B1 (ko) * 1996-02-29 2005-05-09 주식회사 엘지생명과학 수두바이러스의당단백질을대량발현시키는동물세포주
DE19757767A1 (de) 1997-12-23 1999-07-15 Dade Behring Marburg Gmbh Immunreaktive Bereiche des Glycoproteins gpII des Varicella-Zoster-Virus (VZV)
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014043189A1 (fr) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Virus de l'herpès déficients pour la réplication conditionnelle et leur utilisation dans des vaccins
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
EP3833382A1 (fr) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processus et vaccins
EP3886901A1 (fr) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Procédés de fabrication d'un adjuvant
WO2020245207A1 (fr) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Purification de saponine
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN112142829B (zh) * 2019-06-28 2022-02-22 怡道生物科技(苏州)有限公司 水痘-带状疱疹病毒gE蛋白突变体及其表达方法
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
CN115819616B (zh) * 2021-07-28 2025-04-11 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
EP4169513A1 (fr) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Composition d'adjuvant comprenant des agonistes du sting
EP4558170A1 (fr) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Procédé continu de production de vaccin
WO2025052001A1 (fr) 2023-09-07 2025-03-13 Mnemo Therapeutics Procédés et compositions pour améliorer la réponse immunitaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE118353T1 (de) * 1984-04-06 1995-03-15 Chiron Corp Rekombinanter herpes simplex gb-gd impfstoff.
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (fr) * 1985-08-01 1987-02-25 Merck & Co. Inc. Essai pour anticorps de virus Varicella-Zoster (VZV)
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
JPH02504103A (ja) * 1987-06-30 1990-11-29 ジ・アップジョン・カンパニー 減少したｏ‐連結グリコシレーションを有するウイルスタンパク質

Also Published As

Publication number Publication date
PT94479A (pt) 1991-02-08
EP0405867A1 (fr) 1991-01-02
EP0405867B1 (fr) 1995-03-15
HK1006468A1 (en) 1999-02-26
PT94479B (pt) 1997-05-28
IE902297L (en) 1990-12-27
ATE119939T1 (de) 1995-04-15
DE69017769T2 (de) 1995-07-13
ZA904915B (en) 1991-06-26
IE902297A1 (en) 1991-01-16
CA2019845A1 (fr) 1990-12-27
AU625328B2 (en) 1992-07-09
JPH0349694A (ja) 1991-03-04
AU5779290A (en) 1991-01-03
ES2071770T3 (es) 1995-07-01
DK0405867T3 (da) 1995-05-22
DE69017769D1 (de) 1995-04-20
NZ234222A (en) 1992-03-26
KR910001060A (ko) 1991-01-30
IE66516B1 (en) 1996-01-10
KR0166585B1 (ko) 1999-01-15

Similar Documents

Publication Publication Date Title
CY1933A (en) Novel compounds
AU2618088A (en) Fowlpox virus promoters
IT1229845B (it) Procedimento per la preparazione di perfluoropolieteri perossidici.
DE69007691D1 (de) Verfahren zur Herstellung von Alkylaluminoxanen.
DE59409751D1 (de) Verfahren zur Herstellung von hydroxyphenylsubstituierten 1,3,5-Triazinen
GB2186169B (en) Molecular beam source
DE69010214D1 (de) Lamellenverdampfer.
DE69015912D1 (de) Organosilanverbindungen.
AU636892B2 (en) Halogen substituted diphenylsulfides DO NOT SEAL CASE MAY LAPSE
AU8075887A (en) Heat resistant resin composition by suspension polymerization
DE59006749D1 (de) Kuppelstück zur lösbaren Verbindung von Containern.
DE69012295D1 (de) Verfahren zur Qualitätserhöhung von Leichtolefinströmen.
AU6420390A (en) N-alkyl-p-quinonediimino triazine compounds
AU9121182A (en) Vorrichtung zur durchfuhrung von physiologischen uebungen mit aktiven und passiven bewegungen
IT9019723A0 (it) Procedimento per la modificazione di copolimeri di acrilato
FI960526A0 (fi) Menetelmä kumeenihydroperoksin valmistamiseksi
DE69011798D1 (de) Integralmaterial zur Innenausstattung.
EP0405905A3 (en) Use of isoxazolin-3-one derivatives as antidepressants
ZA905813B (en) Avipox virus promoters
NO903365D0 (no) Opphengspose.
EP0422523A3 (en) Process for the preparation of cyclic carbonates
IT1229510B (it) Procedimento per la preparazione di alfa bromoalcilfluoruri.
EP0431472A3 (en) Resin compositions for light control sheets, and light control sheets prepared from said compositions
DE58906998D1 (de) Verfahren zur Herstellung von 4,5,6-Trichlorpyrimidin.
GB8912569D0 (en) Ion beam source